Loading…
Influence of lymph node involvement or lymphadenectomy on prognosis of patients with borderline ovarian tumors: A systematic review and meta-analysis
Borderline ovarian tumors (BOTs) account for about 15% of all epithelial tumors of the ovary, and around 75% of patients are diagnosed in early stages. Although many of these patients have lymph node involvement (LNI), whether LNI decreases their survival is controversial, raising the question of wh...
Saved in:
| Published in: | Gynecologic oncology 2021-09, Vol.162 (3), p.797-803 |
|---|---|
| Main Authors: | , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c359t-cb07faa6efbcee907d5ec70fd21558d8cc123ff313173ac417739c3e97a817703 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c359t-cb07faa6efbcee907d5ec70fd21558d8cc123ff313173ac417739c3e97a817703 |
| container_end_page | 803 |
| container_issue | 3 |
| container_start_page | 797 |
| container_title | Gynecologic oncology |
| container_volume | 162 |
| creator | Fan, Yu Zhang, Yu-fei Wang, Meng-yao Mu, Yi Mo, Si-ping Li, Jin-ke |
| description | Borderline ovarian tumors (BOTs) account for about 15% of all epithelial tumors of the ovary, and around 75% of patients are diagnosed in early stages. Although many of these patients have lymph node involvement (LNI), whether LNI decreases their survival is controversial, raising the question of whether lymphadenectomy should be performed. We conducted a systematic review and meta-analysis of these questions.
We searched articles related to LNI and lymphadenectomy in patients with BOTs in PubMed, EMBASE, and the Cochrane Central Register of Controlled Trials. Data on rate of LNI, recurrence and survival were pooled and meta-analyzed using a random-effects model. Heterogeneity was evaluated using the I2 test.
A total of 25 studies with 12,503 patients were meta-analyzed. The overall pooled rate of LNI was 10% [95% confidence interval (CI) 0.07–0.13]. LNI was associated with a higher risk of recurrence [odds ratio (OR) 2.23, 95% CI 1.13–4.40]. However, LNI did not significantly affect cause-specific survival [hazard ratio (HR) 1.73, 95% CI 0.99–3.02] or disease-free survival (HR 1.48, 95% CI 0.56–3.92). Similarly, lymphadenectomy did not significantly affect risk of recurrence (OR 0.91, 95% CI 0.57–1.46), overall survival (HR 0.90, 95% CI 0.58–1.40), disease-free survival (HR 0.95, 95% CI 0.61–1.50) or progression-free survival (HR 0.60, 95% CI 0.24–1.49).
LNI appears to increase risk of recurrence in BOT patients, but neither it nor lymphadenectomy appears to influence prognosis. Therefore, lymphadenectomy should be considered only for certain BOT patients, such as those with suspected LNI based on imaging or surgical exploration.
•Lymph node involvement is related to higher risk of recurrence in patients with borderline ovarian tumors.•Neither lymph node involvement nor lymphadenectomy influences survival in patients with borderline ovarian tumors.•Lymphadenectomy should be performed only for certain patients with borderline ovarian tumors. |
| doi_str_mv | 10.1016/j.ygyno.2021.05.033 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2540720240</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S009082582100439X</els_id><sourcerecordid>2540720240</sourcerecordid><originalsourceid>FETCH-LOGICAL-c359t-cb07faa6efbcee907d5ec70fd21558d8cc123ff313173ac417739c3e97a817703</originalsourceid><addsrcrecordid>eNp9kc1u1DAUhS0EokPhCZCQl2wSruPxJEFiUVX8VKrEBtaWx75uPYrtwXamyoPwvnWYwpKVr-RzztU9HyFvGbQM2O7DoV3ulhDbDjrWgmiB82dkw2AUzW4Q43OyARihGToxXJBXOR8AgAPrXpILvmVs5DuxIb9vgp1mDBpptHRa_PGehmiQunCK0wk9hkJjOv8ogwF1iX6hMdBjinchZpdX51EVV6WZPrhyT_cxGUyTCzX1pJJTgZbZx5Q_0iual1zQV72mCU8OH6gKhnosqlFBTUtNfE1eWDVlfPP0XpKfXz7_uP7W3H7_enN9ddtoLsbS6D30Vqkd2r1GHKE3AnUP1nRMiMEMWrOOW8sZZz1Xesv6no-a49iroc7AL8n7c2695deMuUjvssZpUgHjnGUnttDXfrerlJ-lOsWcE1p5TM6rtEgGcuUhD_IPD7nykCBk5VFd754WzHuP5p_nL4Aq-HQWYD2zlpFk1m7FYVyqVUsT3X8XPALAvKGo</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2540720240</pqid></control><display><type>article</type><title>Influence of lymph node involvement or lymphadenectomy on prognosis of patients with borderline ovarian tumors: A systematic review and meta-analysis</title><source>ScienceDirect Freedom Collection 2022-2024</source><creator>Fan, Yu ; Zhang, Yu-fei ; Wang, Meng-yao ; Mu, Yi ; Mo, Si-ping ; Li, Jin-ke</creator><creatorcontrib>Fan, Yu ; Zhang, Yu-fei ; Wang, Meng-yao ; Mu, Yi ; Mo, Si-ping ; Li, Jin-ke</creatorcontrib><description>Borderline ovarian tumors (BOTs) account for about 15% of all epithelial tumors of the ovary, and around 75% of patients are diagnosed in early stages. Although many of these patients have lymph node involvement (LNI), whether LNI decreases their survival is controversial, raising the question of whether lymphadenectomy should be performed. We conducted a systematic review and meta-analysis of these questions.
We searched articles related to LNI and lymphadenectomy in patients with BOTs in PubMed, EMBASE, and the Cochrane Central Register of Controlled Trials. Data on rate of LNI, recurrence and survival were pooled and meta-analyzed using a random-effects model. Heterogeneity was evaluated using the I2 test.
A total of 25 studies with 12,503 patients were meta-analyzed. The overall pooled rate of LNI was 10% [95% confidence interval (CI) 0.07–0.13]. LNI was associated with a higher risk of recurrence [odds ratio (OR) 2.23, 95% CI 1.13–4.40]. However, LNI did not significantly affect cause-specific survival [hazard ratio (HR) 1.73, 95% CI 0.99–3.02] or disease-free survival (HR 1.48, 95% CI 0.56–3.92). Similarly, lymphadenectomy did not significantly affect risk of recurrence (OR 0.91, 95% CI 0.57–1.46), overall survival (HR 0.90, 95% CI 0.58–1.40), disease-free survival (HR 0.95, 95% CI 0.61–1.50) or progression-free survival (HR 0.60, 95% CI 0.24–1.49).
LNI appears to increase risk of recurrence in BOT patients, but neither it nor lymphadenectomy appears to influence prognosis. Therefore, lymphadenectomy should be considered only for certain BOT patients, such as those with suspected LNI based on imaging or surgical exploration.
•Lymph node involvement is related to higher risk of recurrence in patients with borderline ovarian tumors.•Neither lymph node involvement nor lymphadenectomy influences survival in patients with borderline ovarian tumors.•Lymphadenectomy should be performed only for certain patients with borderline ovarian tumors.</description><identifier>ISSN: 0090-8258</identifier><identifier>EISSN: 1095-6859</identifier><identifier>DOI: 10.1016/j.ygyno.2021.05.033</identifier><identifier>PMID: 34119365</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Carcinoma, Ovarian Epithelial - mortality ; Carcinoma, Ovarian Epithelial - surgery ; Female ; Humans ; Lymph Node Excision - adverse effects ; Lymphatic Metastasis ; Ovarian Neoplasms - mortality ; Ovarian Neoplasms - surgery</subject><ispartof>Gynecologic oncology, 2021-09, Vol.162 (3), p.797-803</ispartof><rights>2021 Elsevier Inc.</rights><rights>Copyright © 2021 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c359t-cb07faa6efbcee907d5ec70fd21558d8cc123ff313173ac417739c3e97a817703</citedby><cites>FETCH-LOGICAL-c359t-cb07faa6efbcee907d5ec70fd21558d8cc123ff313173ac417739c3e97a817703</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,786,790,27957,27958</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34119365$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Fan, Yu</creatorcontrib><creatorcontrib>Zhang, Yu-fei</creatorcontrib><creatorcontrib>Wang, Meng-yao</creatorcontrib><creatorcontrib>Mu, Yi</creatorcontrib><creatorcontrib>Mo, Si-ping</creatorcontrib><creatorcontrib>Li, Jin-ke</creatorcontrib><title>Influence of lymph node involvement or lymphadenectomy on prognosis of patients with borderline ovarian tumors: A systematic review and meta-analysis</title><title>Gynecologic oncology</title><addtitle>Gynecol Oncol</addtitle><description>Borderline ovarian tumors (BOTs) account for about 15% of all epithelial tumors of the ovary, and around 75% of patients are diagnosed in early stages. Although many of these patients have lymph node involvement (LNI), whether LNI decreases their survival is controversial, raising the question of whether lymphadenectomy should be performed. We conducted a systematic review and meta-analysis of these questions.
We searched articles related to LNI and lymphadenectomy in patients with BOTs in PubMed, EMBASE, and the Cochrane Central Register of Controlled Trials. Data on rate of LNI, recurrence and survival were pooled and meta-analyzed using a random-effects model. Heterogeneity was evaluated using the I2 test.
A total of 25 studies with 12,503 patients were meta-analyzed. The overall pooled rate of LNI was 10% [95% confidence interval (CI) 0.07–0.13]. LNI was associated with a higher risk of recurrence [odds ratio (OR) 2.23, 95% CI 1.13–4.40]. However, LNI did not significantly affect cause-specific survival [hazard ratio (HR) 1.73, 95% CI 0.99–3.02] or disease-free survival (HR 1.48, 95% CI 0.56–3.92). Similarly, lymphadenectomy did not significantly affect risk of recurrence (OR 0.91, 95% CI 0.57–1.46), overall survival (HR 0.90, 95% CI 0.58–1.40), disease-free survival (HR 0.95, 95% CI 0.61–1.50) or progression-free survival (HR 0.60, 95% CI 0.24–1.49).
LNI appears to increase risk of recurrence in BOT patients, but neither it nor lymphadenectomy appears to influence prognosis. Therefore, lymphadenectomy should be considered only for certain BOT patients, such as those with suspected LNI based on imaging or surgical exploration.
•Lymph node involvement is related to higher risk of recurrence in patients with borderline ovarian tumors.•Neither lymph node involvement nor lymphadenectomy influences survival in patients with borderline ovarian tumors.•Lymphadenectomy should be performed only for certain patients with borderline ovarian tumors.</description><subject>Carcinoma, Ovarian Epithelial - mortality</subject><subject>Carcinoma, Ovarian Epithelial - surgery</subject><subject>Female</subject><subject>Humans</subject><subject>Lymph Node Excision - adverse effects</subject><subject>Lymphatic Metastasis</subject><subject>Ovarian Neoplasms - mortality</subject><subject>Ovarian Neoplasms - surgery</subject><issn>0090-8258</issn><issn>1095-6859</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNp9kc1u1DAUhS0EokPhCZCQl2wSruPxJEFiUVX8VKrEBtaWx75uPYrtwXamyoPwvnWYwpKVr-RzztU9HyFvGbQM2O7DoV3ulhDbDjrWgmiB82dkw2AUzW4Q43OyARihGToxXJBXOR8AgAPrXpILvmVs5DuxIb9vgp1mDBpptHRa_PGehmiQunCK0wk9hkJjOv8ogwF1iX6hMdBjinchZpdX51EVV6WZPrhyT_cxGUyTCzX1pJJTgZbZx5Q_0iual1zQV72mCU8OH6gKhnosqlFBTUtNfE1eWDVlfPP0XpKfXz7_uP7W3H7_enN9ddtoLsbS6D30Vqkd2r1GHKE3AnUP1nRMiMEMWrOOW8sZZz1Xesv6no-a49iroc7AL8n7c2695deMuUjvssZpUgHjnGUnttDXfrerlJ-lOsWcE1p5TM6rtEgGcuUhD_IPD7nykCBk5VFd754WzHuP5p_nL4Aq-HQWYD2zlpFk1m7FYVyqVUsT3X8XPALAvKGo</recordid><startdate>202109</startdate><enddate>202109</enddate><creator>Fan, Yu</creator><creator>Zhang, Yu-fei</creator><creator>Wang, Meng-yao</creator><creator>Mu, Yi</creator><creator>Mo, Si-ping</creator><creator>Li, Jin-ke</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202109</creationdate><title>Influence of lymph node involvement or lymphadenectomy on prognosis of patients with borderline ovarian tumors: A systematic review and meta-analysis</title><author>Fan, Yu ; Zhang, Yu-fei ; Wang, Meng-yao ; Mu, Yi ; Mo, Si-ping ; Li, Jin-ke</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c359t-cb07faa6efbcee907d5ec70fd21558d8cc123ff313173ac417739c3e97a817703</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Carcinoma, Ovarian Epithelial - mortality</topic><topic>Carcinoma, Ovarian Epithelial - surgery</topic><topic>Female</topic><topic>Humans</topic><topic>Lymph Node Excision - adverse effects</topic><topic>Lymphatic Metastasis</topic><topic>Ovarian Neoplasms - mortality</topic><topic>Ovarian Neoplasms - surgery</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fan, Yu</creatorcontrib><creatorcontrib>Zhang, Yu-fei</creatorcontrib><creatorcontrib>Wang, Meng-yao</creatorcontrib><creatorcontrib>Mu, Yi</creatorcontrib><creatorcontrib>Mo, Si-ping</creatorcontrib><creatorcontrib>Li, Jin-ke</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Gynecologic oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fan, Yu</au><au>Zhang, Yu-fei</au><au>Wang, Meng-yao</au><au>Mu, Yi</au><au>Mo, Si-ping</au><au>Li, Jin-ke</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Influence of lymph node involvement or lymphadenectomy on prognosis of patients with borderline ovarian tumors: A systematic review and meta-analysis</atitle><jtitle>Gynecologic oncology</jtitle><addtitle>Gynecol Oncol</addtitle><date>2021-09</date><risdate>2021</risdate><volume>162</volume><issue>3</issue><spage>797</spage><epage>803</epage><pages>797-803</pages><issn>0090-8258</issn><eissn>1095-6859</eissn><notes>ObjectType-Article-2</notes><notes>SourceType-Scholarly Journals-1</notes><notes>ObjectType-Feature-1</notes><notes>content type line 23</notes><notes>ObjectType-Undefined-3</notes><abstract>Borderline ovarian tumors (BOTs) account for about 15% of all epithelial tumors of the ovary, and around 75% of patients are diagnosed in early stages. Although many of these patients have lymph node involvement (LNI), whether LNI decreases their survival is controversial, raising the question of whether lymphadenectomy should be performed. We conducted a systematic review and meta-analysis of these questions.
We searched articles related to LNI and lymphadenectomy in patients with BOTs in PubMed, EMBASE, and the Cochrane Central Register of Controlled Trials. Data on rate of LNI, recurrence and survival were pooled and meta-analyzed using a random-effects model. Heterogeneity was evaluated using the I2 test.
A total of 25 studies with 12,503 patients were meta-analyzed. The overall pooled rate of LNI was 10% [95% confidence interval (CI) 0.07–0.13]. LNI was associated with a higher risk of recurrence [odds ratio (OR) 2.23, 95% CI 1.13–4.40]. However, LNI did not significantly affect cause-specific survival [hazard ratio (HR) 1.73, 95% CI 0.99–3.02] or disease-free survival (HR 1.48, 95% CI 0.56–3.92). Similarly, lymphadenectomy did not significantly affect risk of recurrence (OR 0.91, 95% CI 0.57–1.46), overall survival (HR 0.90, 95% CI 0.58–1.40), disease-free survival (HR 0.95, 95% CI 0.61–1.50) or progression-free survival (HR 0.60, 95% CI 0.24–1.49).
LNI appears to increase risk of recurrence in BOT patients, but neither it nor lymphadenectomy appears to influence prognosis. Therefore, lymphadenectomy should be considered only for certain BOT patients, such as those with suspected LNI based on imaging or surgical exploration.
•Lymph node involvement is related to higher risk of recurrence in patients with borderline ovarian tumors.•Neither lymph node involvement nor lymphadenectomy influences survival in patients with borderline ovarian tumors.•Lymphadenectomy should be performed only for certain patients with borderline ovarian tumors.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>34119365</pmid><doi>10.1016/j.ygyno.2021.05.033</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0090-8258 |
| ispartof | Gynecologic oncology, 2021-09, Vol.162 (3), p.797-803 |
| issn | 0090-8258 1095-6859 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2540720240 |
| source | ScienceDirect Freedom Collection 2022-2024 |
| subjects | Carcinoma, Ovarian Epithelial - mortality Carcinoma, Ovarian Epithelial - surgery Female Humans Lymph Node Excision - adverse effects Lymphatic Metastasis Ovarian Neoplasms - mortality Ovarian Neoplasms - surgery |
| title | Influence of lymph node involvement or lymphadenectomy on prognosis of patients with borderline ovarian tumors: A systematic review and meta-analysis |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-09-21T17%3A08%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Influence%20of%20lymph%20node%20involvement%20or%20lymphadenectomy%20on%20prognosis%20of%20patients%20with%20borderline%20ovarian%20tumors:%20A%20systematic%20review%20and%20meta-analysis&rft.jtitle=Gynecologic%20oncology&rft.au=Fan,%20Yu&rft.date=2021-09&rft.volume=162&rft.issue=3&rft.spage=797&rft.epage=803&rft.pages=797-803&rft.issn=0090-8258&rft.eissn=1095-6859&rft_id=info:doi/10.1016/j.ygyno.2021.05.033&rft_dat=%3Cproquest_cross%3E2540720240%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c359t-cb07faa6efbcee907d5ec70fd21558d8cc123ff313173ac417739c3e97a817703%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2540720240&rft_id=info:pmid/34119365&rfr_iscdi=true |